chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 20.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, Inappropriate schedule of product administration
Clinical narrative: Expired vaccine used; Time interval between 2 doses was less than a month; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Time interval between 2 doses was less than a month) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030H21B and 034C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 29-Dec-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 29-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Time interval between 2 doses was less than a month). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Time interval between 2 doses was less than a month) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Patient had no known allergies. Expired vaccine given to the patient with no adverse reactions reported. No treatment medications were reported
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Accidental overdose, Expired product administered
Clinical narrative: Expired vaccine; 0.3ml given as booster; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine) and ACCIDENTAL OVERDOSE (0.3ml given as booster) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 030B21A and 025A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 03-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 01-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 01-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine) and ACCIDENTAL OVERDOSE (0.3ml given as booster). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine) and ACCIDENTAL OVERDOSE (0.3ml given as booster) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine) to be not related. No further causality assessment was provided for ACCIDENTAL OVERDOSE (0.3ml given as booster).    It was unknown whether patient had tested positive for COVID-19.  No concomitant medications were reported.  No adverse events reported. No treatment medications were reported.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, Overdose
Clinical narrative: Expired vaccine used; 0.3ml administered as booster; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and OVERDOSE (0.3ml administered as booster) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A and 042B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 19-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 01-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and OVERDOSE (0.3ml administered as booster). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and OVERDOSE (0.3ml administered as booster) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) to be not related. No further causality assessment was provided for OVERDOSE (0.3ml administered as booster).    It was reported that the patient did not had any adverse reactions.  Concomitant products were not provided. Treatment medications were not reported.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Accidental overdose, Expired product administered, Inappropriate schedule of product administration
Clinical narrative: Expired vaccine used; 0.3ml given as booster; Inappropriate schedule of vaccine administered; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used), ACCIDENTAL OVERDOSE (0.3ml given as booster) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 008C21A and 016B21A) for COVID-19 vaccination.     Concurrent medical conditions included Type 2 diabetes mellitus since 2019, Neuropathy since 2019 and Dyslipidemia. Concomitant products included ATORVASTATIN from 20-Nov-2021 to an unknown date, FISH OIL from April 2021 to an unknown date, GLIMEPIRIDE from April 2021 to an unknown date, PIOGLITAZONE HYDROCHLORIDE (PIOGLITAZON) from June 2021 to an unknown date and METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE (JANUMET) from August 2021 to an unknown date for an unknown indication.   On 27-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 24-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 01-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 01-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used), ACCIDENTAL OVERDOSE (0.3ml given as booster) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used), ACCIDENTAL OVERDOSE (0.3ml given as booster) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) to be not related. No further causality assessments were provided for ACCIDENTAL OVERDOSE (0.3ml given as booster) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered).    No treatment information was provided. The patient stated that he had no known allergies. No adverse reaction was reported.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine used; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A and 0688H21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 31-Dec-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 01-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) to be not related.    Concomitant product information was not provided.  No adverse reaction was reported by the patient.  Treatment information was not provided.   This case was linked to MOD-2022-486834 (Patient Link).
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, Overdose
Clinical narrative: Expired vaccine used; 0.3ml administered as booster dose; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and OVERDOSE (0.3ml administered as booster dose) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 007C21A and 046A21A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension (There was no recent changes in condition), Hyperlipidemia (There was no recent changes in condition) and Osteoarthritis (There was no recent changes in condition). Concomitant products included LISINOPRIL from 20-Jan-2022 to an unknown date and HCTZ from 10-Jan-2022 to an unknown date for an unknown indication.   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 08-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 08-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and OVERDOSE (0.3ml administered as booster dose). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and OVERDOSE (0.3ml administered as booster dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) to be not related. No further causality assessment was provided for OVERDOSE (0.3ml administered as booster dose).    The patient had no known allergies. The patient was not diagnosed with COVID-19. The patient was given expired vaccine with no adverse event reported. The patient did not seek medical care. There were no other potential causes for event. Patient did not experience similar events in past No treatment drug was reported.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Accidental overdose, Expired product administered
Clinical narrative: Expired vaccine used; 0.3 administered as booster; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and ACCIDENTAL OVERDOSE (0.3 administered as booster) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 030B21A and 046A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 08-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 08-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). 08-Dec-2021, the patient experienced ACCIDENTAL OVERDOSE (0.3 administered as booster). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and ACCIDENTAL OVERDOSE (0.3 administered as booster) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) to be not related. No further causality assessment was provided for ACCIDENTAL OVERDOSE (0.3 administered as booster).    No concomitant medications were provided. No treatment medications were provided. Expired vaccine was given with no adverse reaction.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Accidental overdose, Expired product administered
Clinical narrative: Expired vaccine given; 0.3ml given as booster; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine given) and ACCIDENTAL OVERDOSE (0.3ml given as booster) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 038B21A and 042B21-2A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 13-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 08-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 08-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine given) and ACCIDENTAL OVERDOSE (0.3ml given as booster). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine given) and ACCIDENTAL OVERDOSE (0.3ml given as booster) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (Expired vaccine given) to be not related. No further causality assessment was provided for ACCIDENTAL OVERDOSE (0.3ml given as booster).    No concomitant medications were reported.  Expired vaccine given with no adverse events reported.  It was unknown whether patient had tested positive for COVID-19.  No treatment medications were reported.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, Overdose
Clinical narrative: 0.3ml given as booster instead of 0.25 ml; 9 patients received expired vaccine in November and December; This spontaneous case was reported by a nurse and describes the occurrence of OVERDOSE (0.3ml given as booster instead of 0.25 ml) and EXPIRED PRODUCT ADMINISTERED (9 patients received expired vaccine in November and December) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 037C21A and 043B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 30-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 28-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 15-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .3 milliliter. On 15-Dec-2021, the patient experienced OVERDOSE (0.3ml given as booster instead of 0.25 ml). 15-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (9 patients received expired vaccine in November and December). At the time of the report, OVERDOSE (0.3ml given as booster instead of 0.25 ml) and EXPIRED PRODUCT ADMINISTERED (9 patients received expired vaccine in November and December) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (9 patients received expired vaccine in November and December) to be not related. No further causality assessment was provided for OVERDOSE (0.3ml given as booster instead of 0.25 ml).    Patient's allergies related to medication, food and other product was unknown. It was unknown if the patient has ever been diagnosed with/ tested positive for COVID-19. Acute illnesses at the time of vaccination and up to one month before was unknown. Chronic or long-standing health conditions were unknown. No concomitant medication information was provided. Prescriptions, over-the-counter medications, dietary supplements, or herbal remedies being taken at the time of vaccination and/ or at the time of adverse event was unknown. The patient had no adverse event with the expired vaccine. The event did not cause the patient to seek medical care. There was no other potential cause. The patient had not experienced similar event in the past. No treatment medication information was provided.   This case was linked to MOD-2022-486834 (Patient Link).
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: Tested positive for COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (Tested positive for COVID-19) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination.     Concurrent medical conditions included Peanut allergy.    On 22-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Sep-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Tested positive for COVID-19). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) at an unspecified dose and frequency. At the time of the report, SARS-COV-2 TEST POSITIVE (Tested positive for COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 25-Sep-2021, SARS-CoV-2 test: positive (Positive) Positive. On 26-Feb-2022, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication were reported.  Patient got the first dose of Moderna COVID-19 vaccination on 22/Sep/2021. That same week she tested positive for COVID-19 (25/Sep/2021). As she was going to schedule her appointment to get the second vaccination, she ended up testing positive for COVID-19 a second time on 26/Feb/2022. It had now been more than 42 days and she had not received her second Moderna COVID-19 vaccination. Patient also reported that her weight Fluctuates.  Company Comment: This spontaneous case concerns a 25-year-old, female patient with no medical history reported, who experienced the unexpected, non-serious AESI of SARS-CoV-2 test positive. The patient tested positive for COVID-19 3 days after administration of the first dose of the Moderna mRNA-1273 vaccine. The patient took Tylenol (paracetamol) for an unknown indication. The benefit-risk relationship of the Moderna mRNA-1273 vaccine is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a 25-year-old, female patient with no medical history reported, who experienced the unexpected, non-serious AESI of SARS-CoV-2 test positive. The patient tested positive for COVID-19 3 days after administration of the first dose of the Moderna mRNA-1273 vaccine. The patient took Tylenol (paracetamol) for an unknown indication. The benefit-risk relationship of the Moderna mRNA-1273 vaccine is not affected by this report.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046D21A) for COVID-19 vaccination.     The patient's past medical history included Hepatitis C in 2015. Previously administered products included for Hepatitis C: Harvoni. Past adverse reactions to the above products included No adverse event with Harvoni. Concurrent medical conditions included Arthritis.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, the patient experienced PAIN IN EXTREMITY (Sore arm). At the time of the report, PAIN IN EXTREMITY (Sore arm) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Patient never had positive COVID-19 test or diagnosis. No Concomitant information was reported. No Treatment information was reported.   This case was linked to MOD-2022-498505 (Patient Link).
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Biopsy, Dry skin, Eczema, Headache, Hiccups
Clinical narrative: Eczema; Dry skin; Bleeding skin when scratching; Hiccups; Hives, Hives in hands and hair; Itchiness all over the body; Headache; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives, Hives in hands and hair), PRURITUS (Itchiness all over the body), ECZEMA (Eczema), HICCUPS (Hiccups) and DRY SKIN (Dry skin) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013H21A, 008C21A and 030B2A1) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Dec-2021, the patient experienced HEADACHE (Headache) and NAUSEA (Nausea). On 09-Dec-2021, the patient experienced URTICARIA (Hives, Hives in hands and hair) and PRURITUS (Itchiness all over the body). On 26-Feb-2022, the patient experienced HICCUPS (Hiccups). On an unknown date, the patient experienced ECZEMA (Eczema), DRY SKIN (Dry skin) and SKIN HAEMORRHAGE (Bleeding skin when scratching). At the time of the report, URTICARIA (Hives, Hives in hands and hair), PRURITUS (Itchiness all over the body), HICCUPS (Hiccups), HEADACHE (Headache) and NAUSEA (Nausea) had not resolved and ECZEMA (Eczema), DRY SKIN (Dry skin) and SKIN HAEMORRHAGE (Bleeding skin when scratching) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: 2 biopsies of his skin 2 biopsies of his skin.         Treatment was Steroids and creams for the hives. Patient experienced headache and nausea since 02Dec2021 Patient reported that he has not been able to drive, go to the supermarket or eat in restaurants and developed this symptoms he has spent over 1000 dollars on medication and medical services. Dermatologist told him that these symptoms are most likely vaccine related and that he should not get another booster dose. No Concomitant use were reported
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Nausea, Pruritus, Skin haemorrhage, Urticaria
Clinical narrative: Eczema; Dry skin; Bleeding skin when scratching; Hiccups; Hives, Hives in hands and hair; Itchiness all over the body; Headache; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Hives, Hives in hands and hair), PRURITUS (Itchiness all over the body), ECZEMA (Eczema), HICCUPS (Hiccups) and DRY SKIN (Dry skin) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013H21A, 008C21A and 030B2A1) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Dec-2021, the patient experienced HEADACHE (Headache) and NAUSEA (Nausea). On 09-Dec-2021, the patient experienced URTICARIA (Hives, Hives in hands and hair) and PRURITUS (Itchiness all over the body). On 26-Feb-2022, the patient experienced HICCUPS (Hiccups). On an unknown date, the patient experienced ECZEMA (Eczema), DRY SKIN (Dry skin) and SKIN HAEMORRHAGE (Bleeding skin when scratching). At the time of the report, URTICARIA (Hives, Hives in hands and hair), PRURITUS (Itchiness all over the body), HICCUPS (Hiccups), HEADACHE (Headache) and NAUSEA (Nausea) had not resolved and ECZEMA (Eczema), DRY SKIN (Dry skin) and SKIN HAEMORRHAGE (Bleeding skin when scratching) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: 2 biopsies of his skin 2 biopsies of his skin.         Treatment was Steroids and creams for the hives. Patient experienced headache and nausea since 02Dec2021 Patient reported that he has not been able to drive, go to the supermarket or eat in restaurants and developed this symptoms he has spent over 1000 dollars on medication and medical services. Dermatologist told him that these symptoms are most likely vaccine related and that he should not get another booster dose. No Concomitant use were reported
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Moderna dose administered after 30-day Use By Date/1 Patient was administered expired dose; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna dose administered after 30-day Use By Date/1 Patient was administered expired dose) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 084J21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna dose administered after 30-day Use By Date/1 Patient was administered expired dose). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna dose administered after 30-day Use By Date/1 Patient was administered expired dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication details were reported.  No treatment information details were reported.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: A little fatigue; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (A little fatigue) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised, Seasonal allergy and Immune thrombocytopenia (No change in condition) since 1996. Concomitant products included PREDNISONE, MULTIVITAMIN [VITAMINS NOS] and CALCIUM for an unknown indication.    On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jan-2021, the patient experienced FATIGUE (A little fatigue). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Fatigue, at an unspecified dose and frequency. On 31-Jan-2021, FATIGUE (A little fatigue) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       The patient not had COVID  positive test or diagnosis. The patient didn't receive no other vaccines 1-month prior receiving Moderna COVID-19 vaccine. The patient didn't seek medical care. No   This case was linked to MOD-2022-498749, MOD-2022-498874 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: storing their Moderna in the refrigerator and administering it until its expiration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (storing their Moderna in the refrigerator and administering it until its expiration date) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (storing their Moderna in the refrigerator and administering it until its expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (storing their Moderna in the refrigerator and administering it until its expiration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medication was reported.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Pain, Pyrexia
Clinical narrative: Achy; Fatigue; 100 degree Fahrenehit fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Achy), FATIGUE (Fatigue) and PYREXIA (100 degree Fahrenehit fever) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 24M20A and 039K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy (seasonal allergies), Immunocompromised and Immune thrombocytopenia (no change in recent status such as improvement or worsening) since 1996. Concomitant products included PREDNISONE, MULTIVITAMINS [VITAMINS NOS] and CALCIUM for an unknown indication.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Feb-2021, the patient experienced PAIN (Achy), FATIGUE (Fatigue) and PYREXIA (100 degree Fahrenehit fever). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Fever, Fatigue and Ache, at an unspecified dose and frequency. On 01-Mar-2021, PAIN (Achy), FATIGUE (Fatigue) and PYREXIA (100 degree Fahrenehit fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Feb-2021, Body temperature: 100 degree fahreneheit (High) 100 degree Fahreneheit : fever.         The patient did not undergo any COVID test or never been diagnosed with COVID disease before.   This case was linked to MOD-2022-498720, MOD-2022-498874 (Patient Link).
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: gave booster dose to a 17 year old/primary series completead by a 17 year old; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (gave booster dose to a 17 year old/primary series completead by a 17 year old) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008c21, 008c21 and 022j21) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Feb-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (gave booster dose to a 17 year old/primary series completead by a 17 year old). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (gave booster dose to a 17 year old/primary series completead by a 17 year old) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient height was reported as F feet 11 Inches.  The patient had no known allergies. Patient never tested positive/ diagnosed for COVID. Other vaccines given within 1 month prior to Moderna COVID-19 vaccine was reported as no.   No concomitant medications were provided.  Reporter stated that the patient was fine.  No treatment medications were provided.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Inappropriate schedule of product administration
Clinical narrative: A little fatigue; Immunocompromised patient received 3rd dose 6 months after 2nd dose (off schedule); This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (A little fatigue) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Immunocompromised patient received 3rd dose 6 months after 2nd dose (off schedule)) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017E21A, 24M20A and 039K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Immunocompromised and Immune thrombocytopenia (No Change in condition) since 1996. Concomitant products included PREDNISONE, MULTIVITAMINS [VITAMINS NOS] and CALCIUM for an unknown indication.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Aug-2021, the patient experienced FATIGUE (A little fatigue) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Immunocompromised patient received 3rd dose 6 months after 2nd dose (off schedule)). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) ongoing since an unknown date for Adverse event, at an unspecified dose and frequency. In August 2021, FATIGUE (A little fatigue) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Immunocompromised patient received 3rd dose 6 months after 2nd dose (off schedule)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient did not test or diagnosed COVID positive, and she did not take other vaccines within 1 month prior to Moderna COVID-19 vaccine. She had not experienced a similar event in past.  It was reported that for 3rd dose she just felt a little fatigue the day she got the vaccine, but next day she felt fine again.
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.  No Medical History information was reported.  On 01-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   Concomitant medication of the patient was not reported.  The patient had no other side effects.  No treatment information was provided by the reporter.   This case was linked to MOD-2022-498658 (Patient Link).
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia, Pyrexia
Clinical narrative: fever; body aches; joint pain; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), MYALGIA (body aches) and ARTHRALGIA (joint pain) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014C21A and 036B21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: FLU VACCINE VII in September 2021. Past adverse reactions to the above products included No adverse event with FLU VACCINE VII. Concurrent medical conditions included Drug allergy (Erythromycin) and Drug allergy (Z-Pack).   On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 02-May-2021, the patient experienced PYREXIA (fever), MYALGIA (body aches) and ARTHRALGIA (joint pain). At the time of the report, PYREXIA (fever), MYALGIA (body aches) and ARTHRALGIA (joint pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was reported. No concomitant medication was reported.   This case was linked to MOD-2022-498916 (Patient Link).
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Poor quality product administered, Product storage error
Clinical narrative: patients receives booster dose after more than 30 days of refrigerator storages; patients receives booster dose after more than 30 days of refrigerator storages; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT STORAGE ERROR (patients receives booster dose after more than 30 days of refrigerator storages) and POOR QUALITY PRODUCT ADMINISTERED (patients receives booster dose after more than 30 days of refrigerator storages) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033h21a) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer (First dose) on 22-Apr-2021 and Pfizer (Second dose) on 15-May-2021. Past adverse reactions to the above products included No adverse reaction with Pfizer and Pfizer. Concomitant products included CITALOPRAM, GABAPENTIN, NYSTATIN, HYDROCORTISONE, NYSTATIN (NYSTOP) and GUANFACINE for an unknown indication.    On 01-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Jan-2022, the patient experienced PRODUCT STORAGE ERROR (patients receives booster dose after more than 30 days of refrigerator storages). On 01-Mar-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (patients receives booster dose after more than 30 days of refrigerator storages). At the time of the report, PRODUCT STORAGE ERROR (patients receives booster dose after more than 30 days of refrigerator storages) and POOR QUALITY PRODUCT ADMINISTERED (patients receives booster dose after more than 30 days of refrigerator storages) outcome was unknown.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient did not have allergy and any medical history relating to mentioned adverse event and both acute and chronic illness at the time of vaccination. Concomitant medication also included Topical ointment. It was reported that, the vaccine was moved from the Freezer to the refrigerator on the 26-Jan-2022 and two doses were administered to two patients 01-Mar-2022. Vial didn't undergo temperature excursions. Patient had not ever tested COVID positive. Patient had not taken any vaccine one month prior to Moderna COVID-19 Vaccine. Treatment medication was not reported.  This case was linked to MOD-2022-498910 (Patient Link).
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Poor quality product administered, Product storage error
Clinical narrative: patients receives booster dose after more than 30 days of refrigerator storages; patients receives booster dose after more than 30 days of refrigerator storages; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT STORAGE ERROR (patients receives booster dose after more than 30 days of refrigerator storages) and POOR QUALITY PRODUCT ADMINISTERED (patients receives booster dose after more than 30 days of refrigerator storages) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033h21a, 016c21a and 016c21a) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Mar-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Jan-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PRODUCT STORAGE ERROR (patients receives booster dose after more than 30 days of refrigerator storages). On 01-Mar-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (patients receives booster dose after more than 30 days of refrigerator storages). At the time of the report, PRODUCT STORAGE ERROR (patients receives booster dose after more than 30 days of refrigerator storages) and POOR QUALITY PRODUCT ADMINISTERED (patients receives booster dose after more than 30 days of refrigerator storages) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient had no allergies related to medications, food and other products. Patient had no covid 19 positive test or diagnosis. Patient did not received any other vaccine within 1 month prior to Moderna COVID-19 vaccine. The vial was initially stored in the refrigerator on 26 Jan 2022 and did not undergo any temperature excursions.  Concomitant medication information was not provided by the reporter.  Treatment information was not provided by the reporter.   This case was linked to MOD-2022-498889 (Patient Link).
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Mechanical urticaria, Pruritus, Rash, Urticaria
Clinical narrative: Less than 2 weeks following my booster shot, my entire body became itchy; followed by diffuse rash and hives. Benadryl taken. Rashes continued daily throughout the day. Sometimes urticaria and other times dermographia. Rashes mostly occurred on arms, chest, back, abdomen and thighs. Rashes would last 30 to 60 minutes and disappear. Using anti-itch/allergy meds. Zyrtec and hydrocortisone cream used as the doctor suggested. After 1 month rashes became less diffuse and smaller; however still occurring. MD added famotidine and recommended to try this for 1 to 2 weeks. Will refer me to allergist. Awaiting appointment.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered, Product storage error
Clinical narrative: 4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date; 4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date) and PRODUCT STORAGE ERROR (4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058H21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date) and PRODUCT STORAGE ERROR (4 doses of the Moderna COVID-19 vaccine administered after the refrigerated 30-day Use By Date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patients did not had any acute or chronic illnesses. The patients had no allergies and had not tested positive for COVID-19. The patients was not taking any concomitant medication.  The patients did not received any other vaccine within 1 month prior to Moderna and at the time of the vaccination. The 1 vial of batch number 058H21A was initially stored in the refrigerator on 18-Jan-2022. The vial did not undergo any temperature excursions. They administered 4 patients in their deltoid muscle, the Moderna COVID-19 Booster dose 0.25ml on the 25-Feb-2022 after the refrigerated 30-day Use By Date policy. The patients was not experiencing any symptoms.  No treatment medication given.   Most recent FOLLOW-UP information incorporated above includes: On 01-Mar-2022: Non-significant follow-up includes reporters email address details.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pyrexia
Clinical narrative: Headache and fever
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Acoustic stimulation tests abnormal, Sudden hearing loss, Tinnitus
Clinical narrative: Sudden hearing loss and tinnitus About 3 months after second shot
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Atrial fibrillation, Blood pressure increased, Bradycardia, COVID-19, Chest pain
Clinical narrative: Patient presented on 12/27/2021 with right facial droop and right sided weakness. He also reports numbness in his lips with blurry vision. He had further complaints of chest pain and shortness of breath.  Patient was admitted for closer monitoring. Infectious work up completed when patient was noted to be febrile 101.8F. IV ABX initiated vancomycin and Zosyn, and patient tested positive for COVID-19. During this hospitalization he was also noted to have afib. Neurology was consulted who recommended repeat MRI however could not be completed due to patient's underlying respiratory status  Went into AFib RVR on 01/08 and was started on amiodarone drip, amiodarone drip was subsequently stopped due to bradycardia   January 13, WBC is 23 which is improved from 27. He is on HFNC 50L 70%. BP is elevated; restarted hydralazine and minoxidil. He continues on meropenem.  January 15, patient has requested discontinuation of HD and oxygen support and requests comfort measures only.   Patient was pronounced expired at 16:25.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Dyspnoea, Facial paralysis, Hemiparesis, Hypoaesthesia oral
Clinical narrative: Patient presented on 12/27/2021 with right facial droop and right sided weakness. He also reports numbness in his lips with blurry vision. He had further complaints of chest pain and shortness of breath.  Patient was admitted for closer monitoring. Infectious work up completed when patient was noted to be febrile 101.8F. IV ABX initiated vancomycin and Zosyn, and patient tested positive for COVID-19. During this hospitalization he was also noted to have afib. Neurology was consulted who recommended repeat MRI however could not be completed due to patient's underlying respiratory status  Went into AFib RVR on 01/08 and was started on amiodarone drip, amiodarone drip was subsequently stopped due to bradycardia   January 13, WBC is 23 which is improved from 27. He is on HFNC 50L 70%. BP is elevated; restarted hydralazine and minoxidil. He continues on meropenem.  January 15, patient has requested discontinuation of HD and oxygen support and requests comfort measures only.   Patient was pronounced expired at 16:25.